US EditionFDA Approves Subcutaneous Leqembi for Treatment of Early Alzheimer Disease
37 Articles
37 Articles
Alzheimer is one of those diseases that we fear. No matter how long we give treatment, the strength and the means to fight it, it always ends up taking away causing damage to patients as much as to others. However, despite this inevitable fatal outcome, medicine continues to believe that one day we can win this fight. Recently, an injection treatment has been approved in the United States and the latter can be done directly from home. Lecanemab,…
Cambridge – The monoclonal antibody lecanemab, previously approved only for intravenous administration as Leqembi, will soon also be available in the US as Leqembi Iqlik for subcutaneous administration, according to the manufacturer. The US Food and Drug Administration (FDA) has approved a switch from intravenous infusions to subcutaneous injections following...
FDA OKs Subcutaneous Lecanemab for Early AD
After 18 months of intravenous administration of lecanemab (Leqembi), patients may now transition to subcutaneous delivery using the Leqembi Iqlik autoinjector. Medscape Medical News Source link : https://www.medscape.com/viewarticle/fda-oks-subcutaneous-lecanemab-maintenance-dosing-early-ad-2025a1000n3r?src=rss Author : Publish date : 2025-09-02 14:05:00 Copyright for syndicated content belongs to the linked Source. The post FDA OKs Subcutaneou…
Coverage Details
Bias Distribution
- 42% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
